OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)

Rickin Popat, Michael B. Cook(University of Oxford), Shirley D’Sa(University College Hospital), Claire Roddie(Cancer Institute (WIA)), Gary Cook(Guy's Hospital), Elizabeth H. Phillips(University of Manchester), Nicholas Counsell(University College London), Mickey Koh(St George's Hospital), Pamela Smith, Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Laura Clifton‐Hadley(Cancer Research UK), Toyin Adedayo(Cancer Research UK), Gary Pratt, Matthew Streetly(King's College - North Carolina), NK Rabin, Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Mary Flanagan Quinn, Dunnya De‐Silva(University of Liverpool), Janet lyons-Lewis(University College London Hospitals NHS Foundation Trust), J Cavenagh, Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Josephine Crowe(Royal United Hospital), Nivette Braganca(Cancer Research UK), John Ashcroft
St George's Online Research Archive (St George's University of London)
June 26, 2017
Cited by 0


Related Papers